Argos Therapeutics, Inc. Stock

ARGSQ

US0402212023

Pharmaceuticals

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-6.22%	+78.50%

19-09-24	Argos Therapeutics, Inc. Went Out of Business	CI
19-09-24	First Amended Liquidation Plan Approved for Argos Therapeutics, Inc.	CI

Valuation: Argos Therapeutics, Inc.

Market Cap	318K 279K 264K 240K 450K 30.49M 453K 3.16M 1.22M 15.56M 1.19M 1.17M 49.99M	P/E 2016	-2.96x	P/E 2017	-0.22x
Enterprise Value	4.58M 4.03M 3.81M 3.46M 6.5M 440M 6.53M 45.66M 17.63M 225M 17.21M 16.84M 722M	EV / Sales 2016	200x	EV / Sales 2017	9.19x
Free-Float	88.73%	Yield 2016 *	-	Yield 2017	-

* Estimated data More valuation ratios

Latest news: Argos Therapeutics, Inc.

19-09-24	Argos Therapeutics, Inc. Went Out of Business	CI
19-09-24	First Amended Liquidation Plan Approved for Argos Therapeutics, Inc.	CI
19-08-30	First Amended Liquidation Plan Filed by Argos Therapeutics, Inc.	CI
19-03-21	Revised Disclosure Statement Approved on Interim Basis for Argos Therapeutics, Inc.	CI
19-03-15	Liquidation Plan and Disclosure Statement Filed by Argos Therapeutics, Inc.	CI
19-02-12	Genexine Inc. and SCM Lifescience Co. completed the acquisition of substantially all of the assets of Argos Therapeutics Inc.	CI
19-01-22	Motion for Asset Sale Approved for Argos Therapeutics, Inc.	CI
19-01-21	Notice of Successful Bidder Filed by Argos Therapeutics, Inc.	CI
19-01-21	Genexine Inc. and SCM Lifescience Co. entered into an asset purchase agreement to acquire substantially all of the assets of Argos Therapeutics Inc. for $11.3 million.	CI
19-01-21	CELLSCRIPT, LLC and Immune and Cell Therapies, LLC cancelled the acquisition of substantially all of the non-cash assets of Argos Therapeutics, Inc..	CI
18-12-20	Bidding Procedure Approved for Argos Therapeutics, Inc.	CI
18-12-06	Argos Therapeutics, Inc. will Change its Ticker to ARGSQ from ARGS	CI
18-12-03	Argos Therapeutics, Inc. Announces Management Changes	CI

More news

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's Arcelis technology platform utilizes biological components from a patient's own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Employees

Sector

Pharmaceuticals

More about the company

Stock Market
Stocks
ARGSQ Stock

As early as today, start finding the best investment opportunities!

Maximize my profits

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARGOS THERAPEUTICS, INC.	-.--%	-6.22%	-	-	567K
MODERNA, INC.	-0.80%	+14.07%	+705.55%	+96.75%	79.4B
REGENERON PHARMACEUTICALS, INC.	-4.54%	-5.75%	+33.40%	-9.86%	78.69B
CSL LIMITED	+0.04%	+0.96%	-8.31%	-27.25%	59.52B
UCB	-0.89%	+0.19%	+7.92%	+172.79%	46.58B
SAMSUNG BIOLOGICS CO.,LTD.	+2.49%	-0.14%	-8.95%	+33.71%	46.53B
BIOGEN INC.	+0.48%	+4.39%	+66.48%	-11.30%	33.63B
INCYTE CORPORATION	+0.75%	+0.14%	+50.93%	+112.97%	25.11B
INNOVENT BIOLOGICS, INC.	-3.56%	-6.10%	+3.11%	+140.98%	22.13B
SWEDISH ORPHAN BIOVITRUM AB	+0.73%	-0.95%	+61.19%	+97.04%	15.31B
Average	-0.41%	+0.85%	+101.26%	+67.31%	40.69B
Weighted average by Cap.	-0.70%	+2.24%	+153.92%	+53.98%

	2016	2017
Net sales	945K 832K 786K 713K 1.34M 90.76M 1.35M 9.41M 3.64M 46.31M 3.55M 3.47M 149M	1.9M 1.67M 1.58M 1.43M 2.69M 182M 2.71M 18.91M 7.3M 93.04M 7.13M 6.98M 299M
Net income	-53.03M -46.64M -44.1M -40M -75.12M -5.09B -75.56M -528M -204M -2.6B -199M -195M -8.35B	-40.58M -35.69M -33.75M -30.61M -57.48M -3.9B -57.82M -404M -156M -1.99B -152M -149M -6.39B
Net Debt	-13.11M -11.53M -10.9M -9.89M -18.57M -1.26B -18.68M -131M -50.41M -642M -49.22M -48.15M -2.06B	4.27M 3.75M 3.55M 3.22M 6.05M 410M 6.08M 42.49M 16.41M 209M 16.02M 15.67M 672M

Argos Therapeutics, Inc. Stock

Stocks

ARGSQ

US0402212023

Pharmaceuticals

Valuation: Argos Therapeutics, Inc.

Latest news: Argos Therapeutics, Inc.

Biopharmaceuticals

Financials

Company Profile